Metraipolis › archive › dc_2bfee7163e6b

Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy — Europe PMC PMID:41203135

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41203135
DOI
10.1016/j.jbc.2025.110909
License (as archived)
solo-consultazione
Archived
2026-11-08T18:52:22.062Z
SHA-256 of the archived text
ff8fb46bfd0ba4e4feb619f3dec9fb12825fead72954e9a08d4a1f342287bd16
Stable URL of this page
https://metraipolis.com/documento/dc_2bfee7163e6b

How to cite

Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy — Europe PMC PMID:41203135 — Europe PMC (en), https://europepmc.org/article/MED/41203135 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2bfee7163e6b (Metraipolis archive dc_2bfee7163e6b, sha256 ff8fb46bfd0ba4e4feb619f3dec9fb12825fead72954e9a08d4a1f342287bd16)
BibTeX
@misc{dc2bfee7163e6b,
  title = {Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy — Europe PMC PMID:41203135},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41203135},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2bfee7163e6b; sha256 ff8fb46bfd0ba4e4feb619f3dec9fb12825fead72954e9a08d4a1f342287bd16},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41203135. Agents can read the archived copy with the MCP tool read_document.